Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Extends Licensing Agreement with Geron

NEW YORK, Sept. 25 (GenomeWeb News) - Transgenomic will provide an additional supply of modified nucleic acid building-block compounds to Geron, which will use the technology to synthesize one of its thiophosphoramidate-based telomerase inhibitor cancer drugs.


Transgenomic CEO Collin D'Silva said the extended non-exclusive licensing agreement will enable Transgenomic to manufacture phosphoramidate-based oligonucleotides and the chemical building blocks required for their synthesis "for use in diagnostic and therapeutic applications by other biotechnology, pharmaceutical and diagnostics companies to the mutual benefit of both Transgenomic and Geron."

 

Geron said it will use the technology to help develop its cancer drug GRN163L, formerly known as GRN719.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.